Vasundra Lourdu
Vasundra Lourdu has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Gayatri Sukumaran
Sri Ramachandra Faculty of Pharmacy, SRIHER (DU), Chennai. Tamil Nadu, India
2 shared publications - Karthik Rajendran
Bioanalytical and Analytical, Scitus Pharma Services Private Ltd, Thirumazhisai-600124, Tamil Nadu, India
1 shared publication - Surya M.
Sri Ramachandra Faculty of Pharmacy, SRIHER (DU), Chennai-600116, Tamil Nadu, India
1 shared publication
Latest Publications
- Open Access
- 28 February 2026
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 1 (42) , 87-94
Seladelpar As a PPAR-δ Agonist in PBC: Pharmacological Insights and Clinical Applications
Primary biliary cholangitis (PBC) is an autoimmune disease that is characterized by the continuous destruction of small bile ducts within the liver, primarily affecting women aged 40-65. The condition leads to cholestasis and potential liver failure, necessitating effective treatment strategies. Seladelpar (MBX-8025) is a novel selective peroxisome proliferator-activated receptor (PPAR)-delta agonist that has been pioneered to address the unmet need in PBC management. Recent trials demonstrate that seladelpar significantly reduces alkaline phosphatase (ALP) levels and improves patients overall biochemical response, particularly in those intolerant or nonresponsive to UDCA. Particularly, seladelpar regulates bile acid metabolism via suppression of CYP7A1 and elevation of FGF21, contributing to its anti-inflammatory and antifibrotic actions. As a promising experimental drug, seladelpar could reshape treatment approach for PBC, providing an alternative treatment for patients who do not respond adequately to existing therapies due to inadequate responses.
- 28 February 2026
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 1 (42) , 87-94
Open AccessSeladelpar As a PPAR-δ Agonist in PBC: Pharmacological Insights and Clinical Applications
Primary biliary cholangitis (PBC) is an autoimmune disease that is characterized by the continuous destruction of small bile ducts within the liver, primarily affecting women aged 40-65. The condition leads to cholestasis and potential liver failure, necessitating effective treatment strategies. Seladelpar (MBX-8025) is a novel selective peroxisome proliferator-activated receptor (PPAR)-delta agonist that has been pioneered to address the unmet need in PBC management. Recent trials demonstrate that seladelpar significantly reduces alkaline phosphatase (ALP) levels and improves patients overall biochemical response, particularly in those intolerant or nonresponsive to UDCA. Particularly, seladelpar regulates bile acid metabolism via suppression of CYP7A1 and elevation of FGF21, contributing to its anti-inflammatory and antifibrotic actions. As a promising experimental drug, seladelpar could reshape treatment approach for PBC, providing an alternative treatment for patients who do not respond adequately to existing therapies due to inadequate responses.
- Open Access
- 7 November 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 381-387
OPTIMIZATION AND VALIDATION OF ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY COUPLED WITH TANDEM MASS SPECTROMETRY FOR QUANTIFICATION OF EFAVIRENZ IN HUMAN PLASMA
Objective: This study presents the optimization and validation of a sensitive, rapid, and reliable ultra-performance liquid chromatography method for the quantification of efavirenz in human plasma, using efavirenz 13C6 as the internal standard. Method: The liquid-phase extraction technique was used to isolate the internal standard and the analyte from human plasma. The extracted samples were analyzed using chromatography on an Acentis® Express 90 Å C18 column (5 cm x 4.6 mm, 2.7µm), elution carried out using a mixture of ammonium acetate buffer (5 mmol) and acetonitrile as the mobile phase (70:30). The flow rate was maintained at 0.6 ml/min with an injection volume of 5 µl. The ionization mode was negative ion electrospray, with a source energy of 150 °C. Results: The linearity of the method was confirmed by a correlation coefficient of 0.9979, and the calibration range for efavirenz was found to be 50.00-5000 ng/ml. The precision and accuracy for both intra-day and inter-day measurements showed a %CV of less than 2.3% which is within the acceptable limit. The total run time was 3 min. The mean percentage recovery was 83.9 %. Conclusion: The developed method offers a significantly reduced run time, enhancing analytical throughput and efficiency compared to previously reported methods with longer durations. This makes it particularly suitable for high-throughput analysis in routine quality control or pharmacokinetic studies.
- 7 November 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 381-387
Open AccessOPTIMIZATION AND VALIDATION OF ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY COUPLED WITH TANDEM MASS SPECTROMETRY FOR QUANTIFICATION OF EFAVIRENZ IN HUMAN PLASMA
Objective: This study presents the optimization and validation of a sensitive, rapid, and reliable ultra-performance liquid chromatography method for the quantification of efavirenz in human plasma, using efavirenz 13C6 as the internal standard. Method: The liquid-phase extraction technique was used to isolate the internal standard and the analyte from human plasma. The extracted samples were analyzed using chromatography on an Acentis® Express 90 Å C18 column (5 cm x 4.6 mm, 2.7µm), elution carried out using a mixture of ammonium acetate buffer (5 mmol) and acetonitrile as the mobile phase (70:30). The flow rate was maintained at 0.6 ml/min with an injection volume of 5 µl. The ionization mode was negative ion electrospray, with a source energy of 150 °C. Results: The linearity of the method was confirmed by a correlation coefficient of 0.9979, and the calibration range for efavirenz was found to be 50.00-5000 ng/ml. The precision and accuracy for both intra-day and inter-day measurements showed a %CV of less than 2.3% which is within the acceptable limit. The total run time was 3 min. The mean percentage recovery was 83.9 %. Conclusion: The developed method offers a significantly reduced run time, enhancing analytical throughput and efficiency compared to previously reported methods with longer durations. This makes it particularly suitable for high-throughput analysis in routine quality control or pharmacokinetic studies.